CLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments
|
|
- Esther O’Neal’
- 8 years ago
- Views:
Transcription
1 Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted standards of medical practice, peer-reviewed medical literature, government agency/program approval status, and other indicia of medical necessity. The purpose of this Clinical Policy is to provide a guide to medical necessity. Benefit determinations should be based in all cases on the applicable contract provisions governing plan benefits ( Benefit Plan Contract ) and applicable state and federal requirements, as well as applicable plan-level administrative policies and procedures. To the extent there are any conflicts between this Clinical Policy and the Benefit Plan Contract provisions, the Benefit Plan Contract provisions will control. Clinical policies are intended to be reflective of current scientific research and clinical thinking. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. Subject Medical necessity criteria for the following treatments for arthritis: Actemra (tocilizumab) Orencia (abatacept) Cimzia (certolizumab) Remicade (infliximab) Enbrel (etanercept) Rituxan (rituximab) Humira (adalimumab) Simponi (golimumab) Kineret (anakinra) Xeljanz (tofacitinib) Ilaris (canakinumab) Description The intent of the criteria is to ensure that patients follow selection elements established by Centene medical policy. Table 1. Targeted DMARDs for the Treatment of Arthritis 1-10 Medication Generic Name Class FDA Approved Indications Cimzia certolizumab pegol Rheumatoid arthritis (RA) & Ankylosing spondylitis (AS) Enbrel etanercept RA, polyarticular juvenile TNF inhibitor idiopathic arthritis (PJIA), AS Humira adalimumab RA, PJIA, AS Remicade infliximab RA, AS Simponi golimumab RA, AS
2 Page: 2 of 18 Medication Generic Name Class FDA Approved Indications Ilaris canakinumab systemic juvenile idiopathic Interleukin (IL)-1 receptor arthritis (SJIA) antagonist Kineret anakinra RA Actemra tocilizumab IL-6 receptor inhibitor RA, PJIA, SJIA Orencia abatacept selective co-stimulation RA, PJIA modulator Rituxan rituximab monoclonal antibody to B RA cells Xeljanz tofactinib JAK inhibitor RA Management Challenge In the United States, nearly 1.5 million people have RA, one of the most common forms of arthritis. 11 RA is an autoimmune disorder of unknown origin that presents as symmetric, erosive synovitis and, in some patients, extraarticular involvement. 11 It is a chronic, progressive disease that may result in joint deformity, disability and premature death. 12 The key treatment goal is to achieve remission, where the patient experiences no active joint inflammation and no erosive or functional deterioration. 12 While complete remission is not always possible, it is important to maintain function for activities of daily living and work, maximize quality of life, preserve recreational activities, and control disease activity. 11 Policy/Criteria It is the policy of Health Plans affiliated with Centene Corporation that the treatment of arthritic conditions is medically necessary for members who meet the following algorithm criteria: Figure 1a: TNF Inhibitors, Actemra, Orencia, and Xeljanz Safety Algorithm Figure 1b: Kineret Safety Algorithm Figure 1c: Rituxan Safety Algorithm Figure 2: Systemic or Polyarticular Juvenile Idiopathic Arthritis Algorithm Figure 3: Ankylosing Spondylitis Algorithm Figure 4a: Rheumatoid Arthritis Algorithm Figure 4b: Rheumatoid Arthritis Algorithm: Use of Rituxan Figure 5: Remicade Initial Authorization Algorithm Figure 6: Re-authorization Algorithm
3 Page: 3 of 18 Figure 1a: TNF Inhibitors, Actemra, Orencia, and Xeljanz Safety Algorithm Has the patient received a prior biologic or Xeljanz through a Centene benefit? Has patient been screened for LTBI with a TB skin test or an interferon gamma release assay in last 12 months? Document TB test result Positive Has active TB been ruled out? Negative Is patient at risk for HBV infection? Currently receiving or has completed treatment for LTBI? Have an active infection (chronic or localized) or malignant disease? Prior to initiating therapy, has HBV infection been ruled out or treatment initiated? Will it be used in combination with another biologic agent or Xeljanz? Remicade Have unstable moderate to severe heart failure? Has patient previously received treatment with Remicade? Actemra Cimzia Orencia Xeljanz Will it be used in combination with a potent immunosuppressant (eg, azathiopurine, cyclosporine)? Enbrel Humira Simponi Does the prescribed maintenance dose exceed the maximum dose listed in Appendix C? Experienced a severe hypersensitivity reaction? What is the diagnosis? Other pjia sjia AS RA appropriate program policy Figure 2a Figure 2b Figure 3 Figure 4a
4 Page: 4 of 18 Figure 1b: Kineret Safety Algorithm Have an active infection (chronic or localized)? Will Kineret be used in combination with another biologic agent? Does the prescribed Kineret dose exceed 100 mg per day? What is the diagnosis? RA CAPS Figure 4a Centene CAPS policy
5 Page: 5 of 18 Figure 1c: Rituxan Safety Algorithm What is the diagnosis? Other RA Age 18 years? Does patient have severe, active infection? Is patient at risk for HBV infection? Prior to initiating therapy, has HBV infection been ruled out or treatment initiated? Will Rituxan be used in combination with another biologic agent? Is patient currently receiving Rituxan through a Centene benefit? Figure 4b Figure 6
6 Page: 6 of 18 Figure 2: Systemic or Polyarticular Juvenile Idiopathic Arthritis Algorithm What is the prescribed agent? Does the patient meet the age requirement for the prescribed medication? (See Appendix G), pjia Enbrel, Humira Orencia, Illaris Actemra Is prescribing physician a rheumatologist? Currently receiving the prescribed biologic through a Centene benefit? Other Figure 6 Tried and had inadequate response to other biologic for pjia through a Centene benefit? 6 months, sjia Does the patient have active systemic features? Request for Actemra or Ilaris? Tried and had inadequate response to trials of NSAIDS unless not clinically warranted? Prior to therapy, did patient s arthritis involve more than 4 joints?, Humira, Enbrel, Orencia, Actemra Tried and had inadequate response to a trial of corticosteroids? Trial of MTX or leflunomide for at least 3 consecutive months? Contraindication or intolerance to corticosteroids? 6 months Intolerant or contraindication to MTX or leflunomide? Inadequate response to MTX or leflunomide? Trial of other nonbiologic DMARD for at least 3 consecutive months? (see appendix F) Had an inadequate response to such therapy? Adherent to prescribed therapy? Intolerant or contraindicated to such therapy? Document last trial of nonbiologic DMARD 6 months
7 Page: 7 of 18 Figure 3: Ankylosing Spondylitis Algorithm What is the prescribed agent? Enbrel, Humira, Remicade, Simponi, Cimzia Other Age 18 years? Is prescribing physician a rheumatologist? Currently receiving the prescribed biologic through a Centene benefit? Figure 6 6 months Enbrel, Humira, Simponi, Cimzia Tried and had inadequate response to another biologic for AS through a Centene benefit?, Remicade Figure 5 Does patient have axial or peripheral disease? Axial disease Peripheral disease Trial of an NSAID or COX-2 inhibitor for at least 3 consecutive months? (Appendix E) Trial of MTX or sulfasalazine for at least 3 consecutive months? Intolerant or contraindication to therapy? Inadequate response to such therapy? Intolerant or contraindicated to therapy? Enbrel, Humira Simponi, Cimzia Document last trial of therapy unless contraindicated Remicade Adherent to such therapy? Document last trial of therapy unless contraindicated Remicade Enbrel Humira Simponi Cimzia 6 months Figure 5 Figure 5 6 months
8 Page: 8 of 18 Figure 4a: Rheumatoid Arthritis Algorithm Is the RA moderate to severely active? Is prescribing physician a rheumatologist? What is the prescribed drug? Simponi Xeljanz Age 18 years? Other biologics Figure 6 Currently receiving the prescribed med through a Centene benefit? 6 months - Other biologics/ Xeljanz Tried and had inadequate response to another biologic or Xeljanz for RA through a Centene benefit? -Remicade Figure 5 Prior to therapy, did patient have 6 or more inflamed joints? Prior to therapy, did patient have at least one of the characteristics in Appendix B? Intolerant or contraindication to either MTX or leflunomide? Had a trial of MTX or leflunomide for at least 3 consecutive months? Inadequate response to either MTX or leflunomide? Trial of other nonbiologic DMARD for at least 3 consecutive months? (see Appendix F) Had an inadequate response to such therapy? Was patient adherent to prescribed therapy? Intolerant or contraindicated to such therapy? Document last trial of nonbiologic DMARD Other biologics, Xeljanz Go to Figure 5 Remicade Simponi Is Simponi being prescribed with methotrexate? 6 months
9 Page: 9 of 18 Figure 4b: Rituxan for Rheumatoid Arthritis Algorithm Will Rituxan be used with MTX? Prior to therapy, did patients have 6 or more inflamed joints? Prior to therapy, did patient have at least one of the characteristics listed in Appendix B? Trial of either MTX or leflunomide for at least 3 consecutive months? Intolerant or contraindication to either MTX or leflunomide? Inadequate response to MTX or leflunomide? Trial of other nonbiologic DMARD for at least 3 consecutive months? (see appendix F) Inadequate response to such therapy? Adherent to prescribed therapy? Intolerant or contraindication to such therapy? Trial of at least 1 TNF inhibitor for at least 3 consecutive months? (See Appendix D) intolerant or contraindication to TNF inhibitors? Inadequate response to prescribed TNF inhibitor? Approve one course of therapy (2-1000mg IV infusions separated by 2 weeks) Document last trial of TNF inhibitor unless contraindicated Adherent to prescribed TNF inhibitor therapy?
10 Page: 10 of 18 Figure 5: Remicade Initial Authorization Algorithm Had an adequate trial of Humira OR Enbrel? Inadequate response, intolerance or a confirmed adverse event to Humira OR Enbrel? Contraindication or intolerance to Humira AND Enbrel? Is methotrexate prescribed with Remicade? Will Remicade be given at 0,2, and 6 weeks then every 8 weeks thereafter? 6 months
11 Page: 11 of 18 Figure 6: Re-authorization Algorithm - Kineret Is patient compliant with Kineret therapy? Actemra, Cimzia, Enbrel, Kineret, Humira, Orencia, Simponi, Xeljanz, Ilaris Did patient demonstrate therapeutic response? - Actemra Enbrel Humira Orencia Simponi Xeljanz Ilaris 12 months What is the prescribed agent? - Cimzia Does prescribed Cimzia dose exceed 400 mg per month? Rituxan Has patient achieved ACR 20 response following Rituxan initial therapy? Has the patient experience any of the following conditions while on Rituxan? (See Appendix H) Has it been at least 6 months since last treatment? Remicade Did patient demonstrate therapeutic response? Approve one additional course of therapy (2-1000mg IV infusions separated by 2 weeks) Experience diminishing efficacy requiring more frequent infusion intervals than every 6 weeks? Does patient have signs and symptoms of liver toxicity? Ankylosing spondylitis What is the diagnosis? RA Will maintenance regimen consist of IV infusion every 8 weeks? 12 months Will maintenance regimen consists of IV infusion every 6 weeks? 12 months
12 Page: 12 of 18 Background The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) provide recommendations on RA drug management and treatment strategies. 13,14 Treatment is targeted to achieve remission or low disease activity, and early aggressive use of disease-modifying anti-rheumatic drugs (DMARDs) is recommended. 13,14 DMARDs can be classified as nonbiologic or biologic agents. Biologic DMARDs can be further classified as anti-tnf biologics or non-tnf biologics. 13 The nonbiologic DMARDs commonly used today are methotrexate (MTX), leflunomide, hydroxychloroquine, minocycline, and sulfasalazine. 13 EULAR considers MTX to be the cornerstone nonbiologic DMARD and recommends including MTX in the initial treatment strategy for patients with early active RA. 14 For patients with early RA and low to moderate disease activity, ACR recommends nonbiologic DMARD monotherapy or combinations depending on presence or absence of poor prognostic features. 13,14 For those patients with early RA who have high disease activity and features of poor prognosis, the ACR recommends initiating treatment with an anti-tnf biologic agent with or without MTX (except infliximab and golimumab, which should be used with MTX) or combination nonbiologic DMARD therapy. 13 In patients with established RA who have moderate to high disease activity despite nonbiologic DMARD therapy, the ACR recommends adding or switching to an anti-tnf biologic, abatacept, or rituximab. 13 For patients with an inadequate response or a loss of response to an anti-tnf biologic agent, switching to a different anti-tnf biologic or a non-tnf biologic is recommended. 13 Similarly, patients with an inadequate response or a loss of response to a non-tnf biologic should switch to another non-tnf biologic or an anti-tnf biologic. 13 Switching between biologic agents is recommended when patients experience an adverse event to a particular agent but require continued treatment for moderate to high disease activity. 13 Xeljanz is the first drug in a new class called Janus kinase (JAK) inhibitors. 10 Xeljanz is an oral, small-molecule selective inhibitor of JAK1, JAK3, and to a lesser extent, JAK2. 15 Inhibition of JAK1 and JAK3 blocks signaling for several cytokines that are important for lymphocyte function, thereby modulating the immune response. 16 In clinical trials, treatment with Xeljanz resulted in higher response rates and improved physical function compared to treatment with placebo. 10,15,16 Xeljanz represents a novel approach, but its ideal place in therapy has yet to be determined. 17 Additional long-term efficacy (both clinical and radiographic endpoints) and safety data are anticipated. 17 The clinical studies showed efficacies of these agents by comparing them with placebo or while taking them with or without methotrexate to achieve an ACR response improvement of 20% within 6 months or more. Each drug used to treat RA was designed into multiple studies to compare patients who have not tried any therapy, failed MTX therapy, or have failed one anti-tnf. Data
13 Page: 13 of 18 showed that infliximab and golimumab are the agents that showed an ACR 20 response only while being used with methotrexate. Juvenile idiopathic arthritis (JIA) is chronic joint inflammation that occurs in children before they reach the age of 16 with no known cause. It may involve one or many joints, causing other symptoms such as fever or rash, and eye inflammation. It is estimated to affect about 300,000 children in the U.S. Polyarticular juvenile idiopathic arthritis (PJIA) is a condition of JIA that affects more than 4 joints after six months of illness. Systemic juvenile idiopathic arthritis (SJIA) is a condition of JIA where patients experience symptoms of rash or fever in addition to joint inflammation 20. NSAIDs and DMARDS are first-line treatment options for both PJIA and SJIA. Biologic agents are considered second line. Actemra and Ilaris are the only biologics that are currently approved for SJIA. For PJIA, Humira, Enbrel, Orencia, and Actemra are currently approved for patients that need to meet specific age requirements (see appendix G). The efficacy of Actemra for the treatment of active SJIA was assessed in patients treated with or without MTX. Each treatment group received infusions every two weeks for 12 weeks with either Actemra or placebo. The primary endpoint was the proportion of patients with at least 30% improvement in JIA ACR (JIA ACR 30) at Week 12 and absence of fever 1. Patients who received Actemra had an 85% response while those with placebo had a 24% response. A similar clinical trial was conducted with Ilaris versus placebo. Ilaris showed a 84% response of JIA ACR 30 while placebo showed 10%. 18 The efficacy of Actemra for the treatment of PJIA was assessed in patients taking a 16 week active treatment then 24-week withdrawal period. The primary endpoint was the proportion of patients with a JIA ACR 30 flare at week 40 relative to week 16. Actemra treated patients (2-17 years of age) experienced significantly fewer disease flares compared to placebo (26% vs. 48%). 1 The efficacy of Enbrel for the treatment of PJIA was assessed in a two-part study where all patients (2-17 years of age) received Enbrel twice daily in Part 1. In part 2, patients with a clinical response at day 90 were randomized to remain on Enbrel or receive placebo for 4 months and assessed for disease flare. 24% of patients remaining on Enbrel experienced a disease flare compared to 77% patients taking placebo. 3 A similar study was done with Humira that including patients that were between ages 4-17 who were receiving MTX with placebo or Humira in the withdrawal period. Those patients who received Humira had significantly lower disease flares compared to placebo, both without MTX (43% vs 71%) and with MTX (37% vs. 65%). 4 For Orencia, patients were 6-17 years of age and was compared to placebo. During the withdrawal phase, Orencia-treated patients significantly fewer disease compared to placebo-treated patients (20% vs. 53%). 6 Ankylosing spondylitis (AS) is chronic inflammation of the hip and pelvic joints that includes the spine (axial AS). Patients with AS experience symptoms of fatigue, back pain, and stiffness in the
14 Actemra Cimzia Enbrel Humira Kineret Orencia Remicade Rituxan Simponi Ilaris Xeljanz CLINICAL POLICY Page: 14 of 18 spine leading to stooped posture. In addition, AS can also progress to affecting the peripheral joints in the arms and legs (peripheral AS) 22. NSAIDs and COX-2 inhibitors are used as first-line agents used for axial AS to reduce pain and decreasing inflammation. Sulfasalazine is the only DMARD that is effective for AS patients with peripheral arthritis. TNF blockers are the only biologics approved for AS that has shown to reduce the inflammatory activity of spinal disease. The efficacy of Enbrel for the treatment of active AS was conducted in patients who were administered with the drug twice a week for 6 months. The primary measure was a 20% improvement in the Assessment in Ankylosing Spondylitis (ASAS) response criteria compared to placebo for a 6-month treatment. At 6 months, ASAS 20 response was achieved for Enbrel and placebo (60% vs. 27%). 3 A similar trial was conducted with Remicade versus placebo. Patients taking Remicade achieved a 60% ASAS 20 response compared an 18% of patients taking placebo. 7 Furthermore; similar trials were also used for Humira, Cimzia, and Simponi. Patients taking Humira achieved a 58% ASAS 20 response compared to 21% patients taking placebo. 4 Patients taking Cimzia achieved a 68-70% response compared to 37% patients taking placebo. 2 Patients taking Simponi achieved 56% response compared to 23% patients taking placebo. 9 Safety The algorithms (Figures 1a-1c) provide details on how each safety concern is addressed. For a summary by medication, refer to Table 2. Table 2. Safety Concerns with DMARDs for Rheumatoid Arthritis 1-10 Safety Concern Active infection X X X X X X X X X X X Active or latent TB X X X X X X X X X Concomitant use with biologics X X X X X X X X X X Concomitant use with potent immunosuppressants X HBV reactivation X X X X X X X X Severe infusion reactions X X Malignancy X X X X X X Heart failure worsening or new onset* X X X X X Severe mucocutaneous reactions X PML X Tumor Lysis Syndrome X
15 Actemra Cimzia Enbrel Humira Kineret Orencia Remicade Rituxan Simponi Ilaris Xeljanz CLINICAL POLICY Page: 15 of 18 Safety Concern Pulmonary toxicity/copd exacerbations X X CNS demyelinating disorders (new onset or exacerbation) X X X X X X X Hematologic abnormalities (eg, cytopenias) X X X X X X X X X Elevated lipids & LFTs X X Serious allergic reactions/anaphylaxis X X X X X X X X X Autoantibody formation/lupus-like syndrome X X X X X Gastrointestinal perforations X X X Hepatic impairment use not recommended X X * Remicade doses > 5 mg/kg are contraindicated in patients with moderate to severe heart failure. Actemra is associated with neutropenia and thrombocytopenia; Xeljanz is associated with lymphopenia, neutropenia, and anemia. Refer to prescribing information for laboratory monitoring and dose adjustment recommendations. Actemra is not recommended in patients with active hepatic disease or hepatic impairment; Xeljanz is not recommended in patients with severe hepatic impairment. Appendices Appendix A: Abbreviation Key CAPS: cryopyrin-associated periodic syndrome CNS: central nervous system CSA: cyclosporin DMARD disease-modifying anti-rheumatic drug HBV: hepatitis B virus IBD: inflammatory bowel disease ITP: immune thrombocytopenic purpura IV: intravenous LFT: liver function test LTBI: latent tuberculosis infection MTX: methotrexate NSAID: non-steroidal anti-inflammatory drug PML: progressive multifocal leukoencephalopathy TB: tuberculosis TNF: tumor necrosis factor SJIA: systemic juvenile idiopathic arthritis PJIA: polyarticular juvenile idiopathic arthritis AS: ankylosing spondylitis RPLS: reversible posterior leukoencephalopathy syndrome
16 Page: 16 of 18 Appendix B: Diagnosis of moderately to severely active rheumatoid arthritis Elevation of erythrocyte sedimentation rate (ESR) and/or serum c-reactive protein (CRP) concentration Positive rheumatoid factor and/or anti-cyclic citrullinated peptide (CCP) Radiography showing evidence of rheumatoid arthritis, including osteopenia and/or joint space narrowing and/or bony erosions and/or loss of cartilage Functional limitation based on the Health Assessment Questionnaire Disability Index (HAQ-DI) Appendix C: Maximum dose requirements For Enbrel, the prescribed maintenance dose may not exceed 50 mg per week For Humira, the prescribed maintenance dose may not exceed 40 mg every other week; if not taking methotrexate, may not exceed 40 mg every week For Simponi, the prescribed dose may not exceed 50 mg monthly Appendix D: Examples of tumor necrosis factor (TNF) inhibitors Cimzia (certolizumab pegol) Enbrel (etanercept) Humira (adalimumab) Remicade (infliximab) Simponi (golimumab) Appendix E: Examples of NSAIDs and COX-2 Inhibitors NSAIDs Diclofenac Indomethacin Diflunisal Ketoprofen Etodolac Meloxicam Flurbiprofen Nabumetone Ibuprofen Naproxen COX-2 inhibitors: Celecoxib Oxaprozin Piroxicam Salsalate Sulindac Appendix F: Other nonbiologic DMARDs Hydroxychloroquine CSA Sulfasalazine Gold Cyclophosphamide Azathioprine Appendix G: Age Requirements of Medications Actemra: for patients with SJIA & PJIA who are 2 years of age or older
17 Page: 17 of 18 Enbrel: for patients with PJIA who are 2 years of age or older Ilaris: for patients with SJIA who are 2 years of age or older Humira: for patients with PJIA who are 4 years of age or older Orencia: for patients with PJIA who are 6 years of age or older Appendix H: Permanently Discontinued Therapy for the Following Conditions with Rituxan Diagnosis of PML Rise in serum creatinine or oligouria Severe infection Hepatitis B virus reactivation Severe mucocutaneous reactions Life-threatening cardiac arrhythmias Bibliography 1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; October Cimzia [package insert]. Smyrna, GA: UCB, Inc.; October Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; vember Humira [package insert]. rth Chicago, IL: Abbott Laboratories; May Kineret [package insert]. Stockholm, Sweden: Biovitrum AB (publ); December Orencia [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; December Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc.; vember Rituxan [package insert]. South San Francisco, CA: Genentech, Inc.; September Simponi [package insert]. Horsham, PA: Janssen Biotech, Inc.; January Xeljanz [package insert]. New York, NY: Pfizer, Inc.; May Centers for Disease Control and Prevention. Rheumatoid arthritis. Accessed July 16, Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376: Singh JA, Furst DE, Bharat A, et al Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5): Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6): Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6): Fox D. Kinase inhibition a new approach to the treatment of rheumatoid arthritis. N Engl J Med. 2012;367(6): Ilaris [package insert]. East Hanover, NJ: vartis Pharmaceuticals Corporation; May 2013.
18 Page: 18 of Ringold, S, Weiss PF, et al Update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2013; 65 (10): Braun J, van den berg R, et al Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Am Rheu Dis. 2011: 70; American College of Rheumatology. Accessed on July 16, Revision Log Date clinical changes. 09/12 Questions rearranged so that patients who have previously received biologic therapy will bypass safety questions related to TB and HBV Combined all reauthorization algorithms into one. Added Xeljanz 07/13 Removed ITP and safety question regarding prior reactions from Rituxan safety 07/13 algorithm Renamed policy to Arthritis Treatments since it covers more than Rheumatoid 07/13 Arthritis Added drugs: Ilaris for SJIA 07/14 Updated background information: JIA, AS Updated safety concerns: Ilaris Added efficacy data for RA, JIA, and AS Added appendices G & H Figure 2a and Figure 2b algorithm joined Figure 2: added Actemra for PJIA, Ilaris for SJIA & patient age requirement Figure 3: Cimzia added for AS Figure 4: Added question requiring Simponi be administered with MTX Figure 5: PsA algorithm removed and to be added to Psoriasis Centene policy Figure 6: now Figure 5, added requiring Remicade be administered with MTX Figure 7: now Figure 6, added Appendix H to algorithm 2014 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation.
Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationRheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationTreatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR
Treatment of Rheumatoid Arthritis in the New Millennium Neal I. Shparago, D.O., FACP, FACR What is RA? Symmetric inflammatory polyarthritis Rheumatoid factor positive in 80% Anti-CCP positive in approximately
More informationPage 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
More informationSpeaking Plainly. Biologic treatment options for rheumatoid arthritis
in association with Plain English Campaign Speaking Plainly Biologic treatment options for rheumatoid arthritis A guide to help healthcare professionals talking to patients with rheumatoid arthritis Foreword
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationMEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before
More informationRheumatoid Arthritis: Constantly Evolving Treatment Approaches
Rheumatoid Arthritis: Constantly Evolving Treatment Approaches Jody Garry, Pharm.D. Primary Care Pharmacy Resident VA Medical Center - Iowa City Presentation Overview Pathophysiology & epidemiology Diagnostic
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationRheumatoid Arthritis Information
Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More informationMedia Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationRheumatoid Arthritis:
Rheumatoid Arthritis Update 2014 Mark Hulsey, MD FACR Rheumatoid Arthritis Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis Palpable synovial
More informationMedicines for Rheumatoid. Arthritis. A Review of the Research for Adults
Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced
More informationRheumatic Diseases, Psoriasis, and Crohn s Disease
Rheumatic Diseases, Psoriasis, and Crohn s Disease What does this handout cover? This handout has information about rheumatic disease, psoriasis, and Crohn s disease. It also has information on how these
More informationREFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,
More informationABOUT RHEUMATOID ARTHRITIS
MEDIA BACKGROUNDER ABOUT RHEUMATOID ARTHRITIS Rheumatoid arthritis (RA) is a type of arthritis (chronic inflammatory polyarthritis) that typically affects hands and feet, although any joint in the body
More informationCan Rheumatoid Arthritis treatment ever be stopped?
Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship robdsimc@tampabay.rr.com Do not pour strange medicines
More informationPain is the most common complaint for which most patients seek rheumatologic. Chronic Pain From Rheumatoid Arthritis
PRINTER-FRIENDLY VERSION AVAILABLE AT PAINMEDICINENEWS.COM Chronic Pain From Rheumatoid Arthritis ROLAND STAUD, MD Director, Musculoskeletal Pain Research Professor University of Florida College of Medicine
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationIn the last decade, there have been major changes in the
233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we
More informationDISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS
DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA APPROVED CODES HEDIS
More informationLet s talk about Arthritis
Let s talk about Arthritis Osteoarthritis Rheumatoid Arthritis Kam Shojania, MD, FRCPC Clinical Professor and Head, St. Paul s, UBC and VGH Divisions of Rheumatology Slides with thanks to: Cheryl Koehn
More informationStandard of care for RA in SA 2013
Standard of care for RA in SA 2013 Background Rheumatoid arthritis (RA) is a chronic inflammatory disease, which if treated inadequately leads to irreversible joint damage, resulting in deformities, disability
More informationIssue date: August 2010
Issue date: August 2010 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Part review of NICE technology appraisal
More informationustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd
ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationpåçííáëü=jéçáåáåéë=`çåëçêíáìã==
påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults
More informationGuidelines for the Pharmaceutical Management of Rheumatoid Arthritis Swedish Society of Rheumatology, April 14, 2011
Guidelines for the Pharmaceutical Management of Rheumatoid Arthritis Swedish Society of Rheumatology, April 14, 2011 Working party: Eva Baecklund, Helena Forsblad d Elia, Carl Turesson Background Our purpose
More informationStakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationRecognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
More informationMaster Thesis in Medicine
RISK OF INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB IN CLINICAL PRACTICE Master Thesis in Medicine Joyce Åkerlund Supervisor: Catharina Lindholm, MD, PhD, Associate Professor Department
More informationA Survey of Barriers to Treatment Access in Rheumatoid Arthritis
A Survey of Barriers to Treatment Access in Rheumatoid Arthritis in France, Germany, Italy, Spain and the UK October 2009 Funding for this report was provided by F. Hoffmann-La Roche Ltd Carolin Miltenburger,
More informationA LTCI Approach to Managing Rheumatoid Arthritis
A LTCI Approach to Managing Rheumatoid Arthritis A bit of Science, a bit of Art, a lot of Perseverance... Stephen K. Holland, MD Senior Vice President & Medical Director Long Term Care Group, Inc. Long
More information(THE CHANGING LANDSCAPE)
Updating the therapeutic strategy in RA What is effective, what is changing in daily practice regarding the use of DMARDs and biological agents in the Balkan countries The Greek experience (THE CHANGING
More informationRecognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
More informationRheumatoid Arthritis. Disease RA Final.indd 2 15. 6. 10. 11:23
Rheumatoid Arthritis Disease RA Final.indd 2 15. 6. 10. 11:23 Understanding what to expect can help you prepare for your transition into treatment. Rheumatoid Arthritis What You Need To Know About Rheumatoid
More informationArthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
More informationRheumatoid Arthritis
What is Rheumatoid Arthritis? Rheumatoid Arthritis (RA) is a chronic and systemic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints
More informationSECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
More informationCritical Issues in School Health Arthritis in the School Setting. Lawrence Zemel MD Tegan Willard RN Connecticut Children s
Critical Issues in School Health Arthritis in the School Setting Lawrence Zemel MD Tegan Willard RN Connecticut Children s Juvenile Rheumatoid Idiopathic Arthritis Definition of JRA (JIA) Persistent arthritis
More informationRheumatoid Arthritis
Rheumatoid Arthritis Carole Callaghan Principal Pharmacist NHS Lothian Aim To update pharmacists on the current management of rheumatoid arthritis and explore ways to implement pharmaceutical care for
More informationMedicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationRheumatoid Arthritis. How are joints in the body designed?
Rheumatoid Arthritis How are joints in the body designed? There are more than 100 joints that connect the body s 206 bones. These joints allow us to move the way we do when we walk to work, throw a ball
More informationNew Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia
June 12, 2015 New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of
More informationBiologic Disease-Modifying Antirheumatic Drugs
Biologic Disease-Modifying Antirheumatic Drugs By Rachel A. Burke, Pharm.D., BCACP; and Nicole D. White, Pharm.D. Reviewed by Jessica F. Farrell, Pharm.D.; Benita E. Galloway, Pharm.D., BCPS; and Heather
More informationTreating the Symptoms of Rheumatoid Arthritis: The Biologics. Comparing Effectiveness, Safety, Side Effects, and Price
Treating the Symptoms of Rheumatoid Arthritis: The Biologics Comparing Effectiveness, Safety, Side Effects, and Price Our Recommendations Injectable drugs referred to as biologic DMARDs (Disease-Modifying
More informationMonoclonal Antibodies in Rheumatic Diseases
320 Monoclonal Antibodies in Rheumatic Diseases Candice Yuvienco, MD, and Stuart Schwartz, MD An i n c r e a s e d u n d e r s ta n d i n g o f t h e immunopathogenesis of rheumatic diseases has dramatically
More informationPatient Input Information Clinical Trials Outcomes Common Drug Review
CDEC FINAL RECOMMENDATION USTEKINUMAB (Stelara Janssen Inc.) Indication: Psoriatic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted
More informationAssessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey
DOI 10.1007/s40744-015-0011-1 ORIGINAL RESEARCH Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey Dana B. DiBenedetti. Xiaolei Zhou. Maria Reynolds. Sarika Ogale. Jennie
More informationNew Approaches for the Treatment of Rheumatoid Arthritis
New Approaches for the Treatment of Rheumatoid Arthritis by Victoria A. Serrano, PharmD, FCSHP Director of Pharmacy, Hillcrest, Residency Program Director UCSD Medical Center Goals and Objectives Goals:
More informationUsing Biologics to Treat: Rheumatoid Arthritis. Comparing Effectiveness, Safety, Side Effects, and Price
Using Biologics to Treat: Rheumatoid Arthritis Comparing Effectiveness, Safety, Side Effects, and Price Contents Our Recommendations........................................... 3 Welcome....................................................
More informationTherapy Trends: Rheumatoid Arthritis -- KOL Insight Module
Brochure More information from http://www.researchandmarkets.com/reports/2583544/ Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module Description: What the future holds: Over the next few years,
More informationDAVID R. MANDEL, M.D., INC. Rheumatologist
DAVID R. MANDEL, M.D., INC. Rheumatologist 2011 NEW THERAPIES IN RHEUMATOID ARTHRITIS AND OSTEOPOROSIS CLINICAL MANIFESTATIONS Rheumatoid arthritis is a chronic systemic autoimmune disease that affects
More informationThere is a way forward.
For adults with moderate to severe Rheumatoid Arthritis (RA) There is a way forward. You can find the RA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for
More informationBiologics... The Story So Far. Biologics. The Story So Far. A Patient Guide to Biologic Therapies in the Treatment of Rheumatoid Arthritis
Biologics... The Story So Far Biologics The Story So Far A Patient Guide to Biologic Therapies in the Treatment of Rheumatoid Arthritis September 2013 Help & information from NRAS NRAS is the only patient-led
More informationOverview of Rheumatology
Overview of Rheumatology Griffin Hospital Mini Med School Stephen Moses, MD Valley Medical Associates 135 Division St. Ansonia, CT 06401 203.735.9354 Topics I. Anatomy of a Joint II. Osteoarthritis III.
More informationYou can find the PsA treatment support you want. You don t have to do this alone.
For adults with active Psoriatic arthritis (Ps a) There is a way forward. You can find the PsA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for the treatment
More informationRheumatoid Arthritis. Compiled by Darreck My Healing Oils notes
Rheumatoid Arthritis Compiled by Darreck My Healing Oils notes What is Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease where the body's immune system attacks normal joint tissues,
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationGiant Spondylitis and Its Effect on Globlogical Therapy
Cytokine and CAM Antagonists and Related Agents Review 01/22/2010 Copyright 2005-2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No
More informationCommercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
More informationCOLORADO BONE & JOINT NEWSLETTER
COLORADO BONE & JOINT NEWSLETTER A publication of Colorado Center for Arthritis & Osteoporosis, PLLC Copyright 2012 VOLUME 4, ISSUE 1 SPRING 2013 W. Edwards Deming, the father of systems thinking and the
More informationYou can find the PsA treatment support you want. You don t have to do this alone.
For adults with active Psoriatic arthritis (Ps a) There is a way forward. You can find the PsA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for the treatment
More informationRheumatoid Arthritis Medicines. A Guide for Adults
Rheumatoid Arthritis Medicines A Guide for Adults Fast Facts Medicines for rheumatoid arthritis (RA) can slow down the disease and reduce damage to joints. They can relieve pain and make it easier to do
More informationArthritis in Older Adults. Ewa Olech, M.D. University of Nevada School of Medicine Las Vegas, NV
Arthritis in Older Adults Ewa Olech, M.D. University of Nevada School of Medicine Las Vegas, NV Objectives Examine the prevalence and course of arthritis in older adults Describe the different types of
More informationInformation on Rheumatoid Arthritis
Information on Rheumatoid Arthritis Table of Contents About Rheumatoid Arthritis 1 Definition 1 Signs and symptoms 1 Causes 1 Risk factors 1 Test and diagnosis 2 Treatment options 2 Lifestyle 3 References
More informationArthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke
Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis
More informationMEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
More informationOnce the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation.
HealthExchange Points For Your Joints An Arthritis Talk Howard Epstein, MD Orthopaedic & Rheumatologic Institute Rheumatic & Immunologic Disease Cleveland Clinic Beachwood Family Health & Surgery Center
More informationRecommendations for Early RA Patients
SUPPLEMENTARY APPENDIX 5: Executive summary of recommendations for patients with early RA, established RA, and high-risk comorbidities Recommendations for Early RA Patients We strongly recommend using
More informationRituximab (MabThera ) in rheumatoid arthritis: non-nice approved indications
Rituximab (MabThera ) in rheumatoid arthritis: non-nice approved indications Lead author: Stephen Erhorn NHS Regional Drug & Therapeutics Centre (Newcastle) July 2011 2011 Summary NICE guidance is extensive
More informationImprovement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for
More informationRheumatoid arthritis: diagnosis, treatment and prognosis. Dr David D Cruz MD FRCP Consultant Rheumatologist
Rheumatoid arthritis: diagnosis, treatment and prognosis Dr David D Cruz MD FRCP Consultant Rheumatologist The Louise Coote Lupus Unit St Thomas Hospital London AMUS meeting London 7 th March 2012 Disclosures
More informationA New Era in Rheumatoid Arthritis Treatment
A New Era in Rheumatoid Arthritis Treatment Jill C. Costello, MD; Paul B. Halverson, MD ABSTRACT Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily manifests as a chronic symmetric
More informationSpecialty DRUGS. For Decision Makers in Managed Care Supplement 1 2011. Focus on. Rheumatoid Arthritis
For Decision Makers in Managed Care Supplement 1 2011 Specialty DRUGS Focus on Rheumatoid Arthritis contents Departments Features 3 Editorial by Kjel A. Johnson, PharmD, Publisher Five points to consider
More informationPSORIATIC ARTHRITIS. » Diagnosis» Symptoms» Treatments» + more
PSORIATIC ARTHRITIS» Diagnosis» Symptoms» Treatments» + more WHAT IS PSORIASIS? PSORIASIS is pronounced sore-eye-ah-sis. It is an autoimmune disease, meaning that certain triggers cause the immune system
More informationNew Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the
More informationMedications Guide March 2015
s Guide March 2015 Arthritis Consumer Experts (ACE) members/patients-at-large consistently request evidence-based information to enable them to have a more meaningful conversation with their rheumatologist
More informationACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)
More informationSystemic Juvenile Adiopathic Arthritis: Treatment Options 15. Alexei A. Grom, MD Cincinnati Children s Hospital Medical Center
Systemic Juvenile Adiopathic Arthritis: Treatment Options 15 Alexei A. Grom, MD Cincinnati Children s Hospital Medical Center Disclosures NIH grants AR059049, AR048929 Consulting fees Novartis, Roche,
More informationDr Sarah Levy Consultant Rheumatology Croydon University Hospital
Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current
More informationInfl ectra for rheumatoid arthritis
Infl ectra for rheumatoid arthritis Some important information to get you started with your treatment This booklet is intended only for use by patients who have been prescribed Inflectra. Introduction
More informationPsoriatic Arthritis. having psoriatic arthritis.
Psoriatic Arthritis having psoriatic arthritis. Psoriatic arthritis is a chronic disease characterized by a form of inflammation of the skin (psoriasis) and joints (inflammatory arthritis). Psoriasis is
More informationMorgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1
Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Faculty of Pharmacy and Pharmaceutical Sciences, 2 Faciluty of Medicine and Dentistry, 3 School
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #337: Tuberculosis Prevention for Psoriasis,Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier National Quality Strategy Domain: Effective Clincal Care
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More information